Bipolar disorder is a debilitating disorder of the brain with a lifetime prevalence of 1.0 % for bipolar I, 1.1 % for bipolar II disorder and 2.4-4.7 % for subthreshold bipolar disorder. Medications, including lithium, have demonstrated efficacy in the treatment of bipolar disorder, but their molecular targets and mode of action are largely unknown. A few studies have begun to shed light on potential targets of lithium treatment that may be involved in lithium's therapeutic effect. We have recently conducted a microarray study of rat frontal cortex following chronic treatment (21 days) with lithium. Chronic treatment with lithium led to a significant (at least 1.5-fold) down-regulation of 151 genes and up-regulation of 57 genes. We discuss our results in the context of previous microarray studies involving lithium and gene-association studies to identify key genes associated with chronic lithium treatment. A number of genes associated with bipolar disorder, including Comt (catechol-O-methyltransferase), Vapa (vesicle-associated membrane protein-associated protein A), Dtnb (dystrobrevin β) and Pkd1 (polycystic kidney disease 1), were significantly altered in our microarray dataset along with genes associated with synaptic transmission, apoptosis and transport among other functions.
experiment involving juvenile mice, several synaptic vesicle genes, cytoskeletal genes, G-protein signalling and cell adhesion genes were altered in amygdala following treatment with therapeutic doses of lithium [4] . McQuillin et al. [5] , in a mouse whole-brain microarray study, demonstrated that 2 weeks of lithium treatment resulted in differential expression of 121 genes, including several myelination genes, protein phosphatase genes, per2 period gene and the gene for metabolic glutamate receptor 3 [5] . A more recent study of whole-brain mRNA from mice treated for 7 days with lithium revealed differential expression (at least 4-fold change) of 19 genes, five of which were verified by qRT-PCR (quantitative real-time PCR): Mt3 (metallothionein 3), Atp1a1 (ATPase Na + /K + transporting α1 polypeptide), Tceb2 [transcription elongation factor B (SIII) polypeptide 2], Psmb5 (proteasome subunit β type 5) and Gnb1 (guaninenucleotide-binding protein β1) [6] . Taken together, these findings demonstrate that lithium affects multiple pathways in brain, which may explain its efficacy and the underlying pathophysiology of bipolar disorder.
We recently investigated the effect of chronic administration (21 days) of lithium (50 mg/kg of body weight per day intraperitoneally, n = 20) on gene expression in rat frontal cortex. Chronic treatment with lithium led to the significant (1.5-fold change, P < 0.05) up-regulation of 57 genes and down-regulation of 151 genes in rat frontal cortex (see Supplementary Table S1 at http://www.biochemsoctrans. org/bst/037/bst0371090add.htm). Table 1 lists the most substantially up-regulated and down-regulated genes on the basis Table 1 Most substantially down-regulated and up-regulated genes in rat frontal cortex following chronic lithium treatment
All genes altered significantly (P < 0.05). Data mined using MAS5, RMA and LiWong GeneData Expressionist software. of fold change. Genes significantly altered by lithium treatment were grouped on the basis of function (Table 1 and Supplementary Tables S1 and S2 at http://www.biochemsoctrans. org/bst/037/bst0371090add.htm), which revealed involvement of genes from multiple biological pathways, such as signal transduction/cell communication, immune response, transport, protein metabolism, nucleic acid regulation/metabolism and cell growth/maintenance. qRT-PCR verified magnitude and direction of change in ten of the genes of interest (Table 2 ).
Down-regulation of genes associated with bipolar disorder
Four of the genes from our microarray dataset {Comt
(dystrobrevin β) and Pkd1 (polycystic kidney disease 1)} have been known previously to be associated with bipolar disorder. COMT metabolizes catecholamines [7] including dopamine [8] [9] [10] . There are two isoforms of COMT derived from the same gene: one that is soluble, and one that is membrane-bound [7] . COMT has drawn much interest as a modulator of prefrontal cortex function, cognitive abilities and the genetic disposition towards schizophrenia [7, 11] and bipolar disorder [7, [11] [12] [13] . An SNP (single nucleotide polymorphism) of COMT has been associated with poorer performance on measures of verbal memory in subjects with bipolar disorder compared with healthy controls [13] . Other studies, however, have found no association between COMT and bipolar disorder [14, 15] . Using SDS/PAGE and Western blotting, we have demonstrated previously a significant reduction (P < 0.0006) in the 24 kDa cytosolic isoform of COMT protein following treatment with lithium [16] , supporting further our qRT-PCR data. A decrease in COMT by lithium would increase dopamine levels and enhance dopaminergic neurotransmission. VAPA associates with VAMP1 and VAMP2 [17] and is widely expressed in brain [18] . VAPA is also required for vesicular neurotransmission, membrane fusion, protein complex assembly and cell motility [19] . Lohoff et al. [20] found two SNPs that associated with bipolar disorder; however, after permutation correction, only one showed a trend towards allelic association (P < 0.066). Further evidence is needed to conclusively associate VAPA with bipolar disorder. Interestingly, studies have revealed reduced levels of VAPA's binding partner, VAMP1, in subjects with bipolar disorder [21, 22] . It has been hypothesized that variations in VAPA may lead to dysfunctional neurotransmission, ultimately leading to clinical phenotypes of depression and mania [20] . Overexpression of VAPA and VAPB (VAMP-associated protein B) cause retention of endoplasmic reticulum membrane proteins by impeding lateral diffusion and their incorporation into transport vesicles [23] . Thus down-regulation of VAPA by lithium may play a role in the facilitation of intracellular transport of membrane proteins. Interestingly, Youngs et al. [4] also observed down-regulation of a number of synaptic vesicle genes, including Vamp1, Rims2 (encoding synaptotagmin 3) and Stxbp1 (syntaxin-binding protein 1) in amygdala following lithium treatment. VAPA, on the other hand, was found to be increased in amygdala 2 weeks after the last lithium dose [4] . This may represent a regional difference, or the restoration of pre-clinical VAPA expression following the end of treatment.
DTNB is a component of the DPC (dystrophin-associated protein complex). The DPC consists of dystrophin and several integral and peripheral membrane proteins, including dystroglycans, sarcoglycans, syntrophins and dystrobrevin α and β. The DPC localizes to the sarcolemma, and its disruption is associated with various forms of muscular dystrophy. In brain, DTNB is found on neurons primarily in the cortex and hippocampus and it is expressed in postsynaptic membranes, suggesting a role in synaptic transmission [24] . Gaysina et al. [25] found evidence for an association of the DTNBP1 (dystrobrevin-binding protein 1) gene with bipolar disorder, and Talbot et al. [26] found a link between DTNBP1 and schizophrenia.
The Pkd1 gene encodes a member of the polycystin protein family (polycystin 1). Pkd1 is found on chromosome 16p, a region linked to bipolar disorder, autism and epilepsy [27] . Polycystin 1 contains a large N-terminal extracellular region, multiple transmembrane domains and a cytoplasmic C-tail. It is an integral membrane protein that functions as a regulator of calcium-permeable cation channels and intracellular calcium homoeostasis. Polycystin 1 is also involved in actin cytoskeleton rearrangement in response to microenvironmental cues and may be involved in synaptic remodelling and plasticity [28] .
Additional genes down-regulated by lithium
Complexins are cytosolic proteins that bind preferentially to syntaxin within the SNARE (soluble N-ethylmaleimidesensitive fusion protein-attachment protein receptor) complex and promote the oligomerization of SNAREs, which, if blocked, prevent vesicular release of neurotransmitters [29] . Further animal studies found that complexins are vital to transmitter release immediately before vesicle fusion [30] . CPLX2 (complexin 2) is a cytosolic protein that binds preferentially to syntaxin within the SNARE complex and promotes the oligomerization of SNAREs. Cplx2-knockout mice display deficits in interactive grooming behaviours and exploratory behaviour [31] . The decrease of both VAPA and CPLX2 expression following treatment with lithium, together with the study by Youngs et al. [4] , suggests that lithium modulates synaptic transmission as part of its efficacy. A down-regulation of Cplx2 by lithium may increase intracellular uptake of the SNARE complex.
The S100 superfamily consists of 22 members which share conserved structural motifs consisting of two EF-hand Ca 2+ -binding domains connected by a hinge region [32] . S100 proteins are involved in multiple intracellular functions, including maintenance of calcium homoeostasis, cytoskeletal rearrangement, transcription and enzyme regulation [32] . S100A8/A9, S100B and S100A11 and other S100 proteins can be secreted and extracellularly exhibit cytokine-like functions related to inflammation [33, 34] . S100A11 has been observed to be overexpressed in colorectal, gastric, prostrate and pancreatic cancers [35] . Previous work by us and others have shown an increase in expression of S100A8, S100A9 and S100A10 in mouse or rat brain in response to chronic treatment with antidepressants and olanzapine [7, 36, 37] . Future studies are needed to determine whether the changes in S100a11 gene expression observed in rat frontal cortex are medication effects or markers of inflammation. A possible explanation for lithium's effect on down-regulating S100 protein may be to exhibit anti-inflammatory and antioxidative responses in the brain.
We observed down-regulation of two genes associated with apoptosis. FAP (fibroblast-activation protein) is overexpressed in chronic liver disease and has been shown to promote apoptosis in two liver cell lines [38] . The downregulation of Fap mRNA in rat frontal cortex in response to chronic treatment with lithium may be an anti-apoptotic mechanism. Bcl-2L1 (also known as Bcl-X) also regulates apoptosis. It codes for two isoforms, Bcl-X S , which is pro-apoptotic and Bcl-X L , which is anti-apoptotic [39] . This gene is important for the survival of differentiating neurons. It is possible that lithium decreases levels of the pro-apoptotic isoform Bcl-X S in favour of Bcl-X L to promote its antiapoptotic effects. Bcl-2L1 can inhibit apoptosis following withdrawal of growth factors [40] , and the smaller variant, Bcl-X S , encodes a protein that inhibits the ability of Bcl-2 to enhance survival of growth factor-deprived cells [40] . Previous work has shown that lithium up-regulates Bcl-X L [41] and Bcl-2 in frontal cortex, hippocampus and striatum [42] . It has been suggested that this action is part of its efficacy in provision of neuroprotective effect to the brain [43] .
Abcb1a (ATP-binding cassette, subfamily B, member 1) codes a transmembrane protein localized to the blood-brain barrier that functions as a drug-transport pump, regulating movement of drugs across the barrier [44] . Decreasing ABCB1A may represent a feedback loop in response to lithium treatment in order to regulate the amount of lithium that may cross the blood-brain barrier.
BMP4 (bone morphogenetic protein 4) is a member of the transforming growth factor-β superfamily. The superfamily includes large families of growth and differentiation factors, which induce cartilage and bone formation and also acts in mesoderm induction, tooth development, limb formation and fracture repair. BMP4 is widely expressed in the brain and may have specialized functions in the adult brain [45] , such as involvement in neural induction and synaptic plasticity. A decrease in BMP4 by lithium may result in altered dendritic remodelling.
Genes up-regulated by lithium
Dnah12 (dynein, axonemal, heavy chain polypeptide 12) was up-regulated in rat frontal cortex. Dyneins are microtubulebased motor proteins that transport membranes in cells [46] . Up-regulation of another dynein gene, Dnah3 (dynein, axonemal, heavy chain polypeptide 3), by paroxetine, an antidepressant, was found after 12 days of administration in rat hippocampus [47] . Disruption of dynein function results in inefficient recycling of transferrin intracellularly [48] . It is possible that lithium helps in recycling of various molecules, such as transferrin.
Fos is part of a gene family encoding nuclear transcription factors. Fos is expressed following stimulation of cells and during differentiation. Lithium is well known to activate Fos in various areas of the brain [49, 50] . The current result is a confirmation of the specificity of this study.
Members of the CREB (cAMP-response element-binding protein)/ATF (activating transcription factor) family are part of signalling cascades that ultimately activate genes involved in neuronal growth and differentiation [51] . Using a rat model, Laifenfeld et al. [52] found that prolonged stress increased phosphorylation of ATF2 in prefrontal cortex. Treatment with the antidepressants desipramine and fluoxetine, reduced phosphorylation of ATF2, suggesting that ATF2 may be involved in the pathology of major depression and a potential target for therapeutic invervention [52] .
Tac1 (tachykinin 1) gene produces substance P and neurokinins that are involved in multiple pathways including inflammation and the potentiation of glutamatergic excitatory synaptic transmission [53] . Tac1-knockout mice display reduced anxiety and depression related behaviours [54] and has been identified as a bipolar disorder candidate gene on the basis of convergent functional genomics [55] .
Ddx3x (DEAD box protein 3, X-linked) was significantly up-regulated following treatment with lithium in rat frontal cortex. DEAD box proteins, characterized by the conserved motif DEAD (Asp-Glu-Ala-Asp), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly.
Other important genes involved in neuropsychiatric illnesses
A number of genes associated with neurotransmission and psychiatric disorders were significantly altered by chronic lithium treatment as determined by microarray analysis. SLC5A7 (solute carrier family 5 member 7) was significantly up-regulated and is a Na + /Cl − transporter responsible for the uptake of choline for the synthesis of acetylcholine. Polymorphisms of SLC5A7 have been associated with major depression [56] . DRD1A (dopamine receptor D1A) was also up-regulated by lithium treatment. DRD1A mediates the actions of dopamine intracellularly by stimulating signalling pathways via adenylate cyclase and has been shown to play important roles in cognition and prefrontal cortex activity [57] . A number of studies have shown an association between DRD1A polymorphisms and bipolar disorder (reviewed in [57] ). Moreover, variations in DRD1A are associated with response to lithium treatment with the G/G genotype resulting in a poorer response to lithium treatment [58] . The increase in DRD1A by lithium would increase dopamine neurotransmission. Htr2a (5-hydroxytryptamine receptor 2A) was significantly down-regulated following lithium treatment in rat frontal cortex and has been associated with bipolar disorder and may mediate the effects of certain antidepressants (reviewed in [3] ). A decrease in HTR2A by lithium would help with improving symptoms of depression. Syngr1 (synaptogyrin 1) was also down-regulated and it encodes a membrane protein associated with synaptic vesicles and is important for neurotransmitter release. Five polymorphisms of Syngr1 have been identified and are associated with schizophrenia and bipolar disorder in an Indian population sample [59] . Also down-regulated and associated with vesicles is Syn3 (synapsin III), encoding a phosphoprotein that is involved in neurotransmitter release. Preliminary results suggest that the SYN3-196 promoter mutation is associated with schizophrenia in Caucasians, but not African Americans [60] .
Conclusions
Our results represent a pilot study examining the effect of lithium on gene expression in rat frontal cortex. We observed significant down-regulation of 151 genes and up-regulation of 57 genes involved with multiple metabolic pathways. As with other microarray studies [4] [5] [6] , we observed that lithium altered the expression of genes involved in multiple biological functions. The direction and magnitude of change for ten genes was verified by qRT-PCR, including four genes that have been associated with bipolar disorder: Comt, Vapa, Dtnb and Pkd1. Our results show that lithium causes changes in levels of several important genes that may be involved in the aetiology and treatment of bipolar disorder. AUT [66] 
